KMID : 0931320230230030159
|
|
´ëÇÑ»óºÎÀ§Àå°ü.Ç︮ÄÚ¹ÚÅÍÇÐȸÁö 2023 Volume.23 No. 3 p.159 ~ p.166
|
|
History and Pharmacological Mechanism of Gastric Acid-suppressive Drugs
|
|
Yeom Dong-Han
Kim Yong-Sung
|
|
Abstract
|
|
|
Gastric acid-related disorders are commonly encountered in clinical practice. Acetylcholine, gastrin, and histamine are physiological agonists that stimulate acid secretion from parietal cells. Histamine plays a decisive role in the transformation of parietal cells into acid-secreting forms. The H+, K+- ATPase proton pump, which represents the final step of acid secretion, translocates from cytoplasmic tubulovesicles to secretory canaliculi upon parietal cell stimulation and facilitates exchange of intracellular H+ with extracellular K+ in a 1:1 ratio. Histamine-2 receptor antagonists and proton pump inhibitors (PPIs) are widely used in clinical practice, and potassium-competitive acid blockers (P-CABs) have gained attention in recent times. P-CABs address the unmet needs of patients who receive conventional PPIs and have broadened the spectrum of drug choices; however, further research is warranted to confirm long-term safety of these drugs. Comprehensive understanding of the mechanisms of actions, characteristics, advantages and disadvantages, and the adverse effect profile is essential for appropriate prescription of gastric acid-suppressive drugs. In this review, we provide a developing history and outline the pharmacological mechanisms underlying various gastric acid-suppressive drugs used in clinical settings.
|
|
KEYWORD
|
|
Fexuprazan, Histamine H2 antagonists, Parietal cells, gastric, Proton pump inhibitors, Tegoprazan
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|